Getty Images
Back in 2016, Merck paid Moderna $200 million to develop personalized cancer vaccines based on people’s mRNA. Today, that doesn’t seem like much of a stretch, but six years ago mRNA technology hadn’t yet found a practical use in the context of a vaccine. Part of the deal was that after proof-of-concept studies, Merck could pay an unspecified amount to co-develop and commercialize the shots with Moderna. According to a recent Freethink* article, that time has come, and the unspecified has been disclosed as $250 million.
